- Home
- REE vs PPCB Comparison
REE vs PPCB Comparison
Compare REE & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REE | PPCB |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 20.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | REE | PPCB |
|---|---|---|
| Price | $0.75 | $0.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.75 | N/A |
| AVG Volume (30 Days) | 112.1K | ★ 264.9K |
| Earning Date | 12-17-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $183,000.00 | N/A |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.61 |
| 52 Week High | $10.24 | $145.46 |
Technical Indicators
Market Signals| Indicator | REE | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | N/A |
| Support Level | $0.65 | N/A |
| Resistance Level | $0.82 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 62.99 | 0.00 |
Price Performance
Historical ComparisonAbout REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.